Journal
NATURE MEDICINE
Volume 8, Issue 5, Pages 485-492Publisher
NATURE AMERICA INC
DOI: 10.1038/nm0502-485
Keywords
-
Funding
- NICHD NIH HHS [HD32573] Funding Source: Medline
- NIDDK NIH HHS [R01 DK053428, DK53428, DK50203, DK17433] Funding Source: Medline
- NIGMS NIH HHS [GM42136] Funding Source: Medline
Ask authors/readers for more resources
The most common mutation in cystic fibrosis, DeltaF508, results in a cystic fibrosis transmembrane conductance regulator (CFTR) protein that is retained in the endoplasmic reticulum (ER). Retention is dependent upon chaperone proteins, many of which require Ca++ for optimal activity. Interfering with chaperone activity by depleting ER Ca++ stores might allow functional DeltaF508-CFTR to reach the cell surface. We exposed several cystic fibrosis cell lines to the ER Ca++ pump inhibitor thapsigargin and evaluated surface expression of DeltaF508-CFTR. Treatment released ER-retained DeltaF508-CFTR to the plasma membrane, where it functioned effectively as a Cl- channel. Treatment with aerosolized calcium-pump inhibitors reversed the nasal epithelial potential defect observed in a mouse model of DeltaF508-CFTR expression. Thus, ER calcium-pump inhibitors represent a potential target for correcting the cystic fibrosis defect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available